{"filing":{"accession_number":"0001193125-26-254708","cik":"0001579428","ticker":"AXSM","company_name":"Axsome Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"axsm-20260603.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1579428/000119312526254708/axsm-20260603.htm"},"events":[{"id":7143,"run_id":6268,"accession_number":"0001193125-26-254708","anchor_item_number":"8.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"summary":"The filing discloses settlement of patent litigation involving SUNOSI® (solriamfetol), a key product for Axsome Therapeutics. Patent litigation settlements can materially affect product exclusivity, market access, and competitive positioning. The press release title explicitly references \"Settlement Resolving All SUNOSI® Patent Litigation,\" indicating comprehensive resolution of patent disputes that would be material to investors assessing the company's intellectual property protection and commercial prospects.","company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","filing_date":"2026-06-03","submitted_at":null,"items":[{"id":3944,"accession_number":"0001193125-26-254708","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"The filing discloses settlement of patent litigation involving SUNOSI® (solriamfetol), a key product for Axsome Therapeutics. Patent litigation settlements can materially affect product exclusivity, market access, and competitive positioning. The press release title explicitly references \"Settlement Resolving All SUNOSI® Patent Litigation,\" indicating comprehensive resolution of patent disputes that would be material to investors assessing the company's intellectual property protection and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:22:19.405069+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3944,"accession_number":"0001193125-26-254708","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"The filing discloses settlement of patent litigation involving SUNOSI® (solriamfetol), a key product for Axsome Therapeutics. Patent litigation settlements can materially affect product exclusivity, market access, and competitive positioning. The press release title explicitly references \"Settlement Resolving All SUNOSI® Patent Litigation,\" indicating comprehensive resolution of patent disputes that would be material to investors assessing the company's intellectual property protection and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:22:19.405069+00:00","company_name":"Axsome Therapeutics, Inc.","ticker":"AXSM","filing_date":"2026-06-03"}]}